Oncothyreon Inc. ONTY today
announced the presentation of final results from the first Phase 1 trial of
ONT-380 at the American Association for Cancer Research Special Conference on
Advances in Breast Cancer Research in San Diego. The results were presented
by Virginia F. Borges, M.D., Associate Professor in the Division of Medical
Oncology, University of Colorado School of Medicine. ONT-380 (also known as
ARRY-380) is an orally active, reversible and selective small-molecule HER2
inhibitor being developed by Oncothyreon in collaboration with Array BioPharma
Inc. (Nasdaq: ARRY), Boulder, Colorado.
The first-in-human Phase 1 trial, with both dose-escalation and expansion
components, enrolled a total of 50 patients, 43 of whom had HER2+ metastatic
breast cancer. In this study, ONT-380 demonstrated an acceptable safety
profile; treatment-related adverse events were primarily Grade 1. Because
ONT-380 is selective for HER2 and does not inhibit EGFR, there was a low
incidence and severity of treatment-related diarrhea, rash and fatigue, side
effects which have been associated with EGFR inhibition. A single patient
experienced Grade 2 treatment-related diarrhea and no patient developed
treatment-related Grade 3 diarrhea; one patient had a Grade 3 rash.
Additionally, there were no treatment-related cardiac events or Grade 4
treatment-related adverse events reported. The maximum tolerated dose of
ONT-380 established in this Phase 1 trial was 600 mg twice daily. The
dose-limiting toxicity was reversible elevation in liver enzymes.
In this trial, 22 HER2+ breast cancer patients with measurable disease were
treated with ONT-380 at doses greater than or equal to 600 mg BID. In this
heavily pretreated patient population, there was a clinical benefit rate
(partial response [n = 3] plus stable disease for at least 6 months [n = 3])
of 27%. Notably, two of the patients with partial responses during treatment
with ONT-380 had confirmed progressions while on prior lapatinib- and
trastuzumab-containing regimens.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in